Citation

Fukai M, Hirosawa T, Takahashi T, Kaneda R, Kikuchi M, Minabe Y. Ther. Adv. Psychopharmacol. 2017; 7(3): 113-117.

Copyright

(Copyright © 2017, SAGE Publishing)

DOI

10.1177/2045125316681750

PMID

unavailable

Abstract

Dopamine supersensitivity is an important consideration for assessing treatment-resistant schizophrenia. The emergence of dopamine supersensitivity might be related to upregulation of dopamine D2 receptor, which engenders tolerance to antipsychotics, rebound psychosis, and tardive dyskinesia (TD). A 24-year-old man with a history of treatment-resistant schizophrenia was hospitalized for treatment of bone fracture sustained during a suicide attempt. After the operation, his clinical symptoms implied malignant catatonia. The patient discontinued antipsychotics without rebound psychosis under clonazepam treatment. His psychotic symptoms were controlled further with 24 mg/day aripiprazole without relapse or worsening. Clonazepam might be an effective option for the management of dopamine supersensitivity psychosis (DSP). © 2016, © The Author(s), 2016.

Language: en

Keywords

clonazepam; dopamine supersensitivity; schizophrenia